NCT00722969

Erlotinib and Sorafenib in Chemonaive Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

A Phase II Study of Erlotinib and Sorafenib in Patients With Locally Advanced and/or Metastatic (Stage IIIb or IV) Non Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 48 (estimated)
• Sponsor: Universitair Ziekenhuis Brussel · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

Patients with advanced or metastatic (stage IIIB-IV) non small cell lung cancer who have not received prior chemotherapy will be treated with erlotinib 150 mg once a day and sorafenib 400 mg twice a day. The objectives of the study are to assess the efficacy and safety of this combination treatment. Additional exploratory study objectives are correlation of biomarkers and imaging modalities potentially predictive for response and (progression free) survival.

Conditions

• Non-Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	sorafenib + erlotinib	sorafenib 400mg b.i.d oral Erlotinib 150 mg o.i.d oral

Timeline

• Start date: 2007-11-01
• Primary completion: 2008-11-01
• Completion: 2009-04-01
• First posted: 2008-07-28
• Last updated: 2009-03-03

Locations

4 sites across 1 country: Netherlands